Oragenics appoints Dr. James Kelly as CMO to lead Phase II concussion trial

ORAGENICS INC

Dr. Kelly will serve as CMO under an independent contractor agreement at $400/hour for 20 hours/month.
He will oversee the Phase II trial of ONP-002, an intranasal NCE for mild traumatic brain injury.
ONP-002 completed a 40-patient Phase I safety study; a 69 million annual concussion market cited.
Dr. Kelly previously led the Marcus Institute for Brain Health and founded the NICoE at Walter Reed.
Company is completing GMP drug manufacturing for the Phase II trial initiation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.